Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company focusing on targeted therapies for RAS-addicted cancers, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. CEO Mark A. Goldsmith will present at a fireside chat on June 12, 2024, at 2:40 p.m. ET. The event will be held at the Loews Miami Beach Hotel in Miami, FL, with a live webcast accessible via the company's website. A replay will be available for 14 days post-conference.
- Participation in a prestigious event like the Goldman Sachs Global Healthcare Conference enhances visibility and credibility.
- CEO Mark A. Goldsmith's involvement highlights leadership and expertise in the industry.
- Live webcast and replay availability increase accessibility for investors and stakeholders.
- No new financial or clinical data were disclosed, which may leave investors seeking concrete updates unsatisfied.
- The impact of the fireside chat on stock performance is uncertain without substantial news or developments.
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference.
Details of the company’s participation are as follows:
- Goldman Sachs 45th Annual Global Healthcare Conference
Conference Dates: June 10-13, 2024
Fireside Chat Time/Date: 2:40 p.m. ET on Wednesday, June 12, 2024
Location: Loews Miami Beach Hotel, Miami, FL
To access a live webcast of the fireside chat, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities include its RAS(ON) mutant-selective inhibitors RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).
![](https://ml.globenewswire.com/media/N2M3ZDNkNmItYmMyNy00ZjMyLTk4MGYtNTBkYWMxYzViYmNjLTEyMDU1ODc=/tiny/Revolution-Medicines-Inc-.png)
FAQ
When will Revolution Medicines participate in the Goldman Sachs 45th Annual Global Healthcare Conference?
What time is the Revolution Medicines fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference?
Where is the Goldman Sachs 45th Annual Global Healthcare Conference being held?
How can I access the webcast of Revolution Medicines' fireside chat?